Matthew Osborne, PA
Physician Assistant · Port Charlotte, FLNPI 1821538653
Payments from drug & device makers
Across 511 payments — averaging $17.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Novo Nordisk$1K
- GSK$885
- Esperion Therapeutics, Inc.$692
- Pfizer$589
- Lilly USA, LLC$547
- plus $3K from 32 others
What the payments were for
- Food & beverage$8,61399%
- Education$801%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 81 | $1,500 |
| Novo Nordisk | 90 | $1,447 |
| GSK | 75 | $885 |
| Esperion Therapeutics, Inc. | 36 | $692 |
| Pfizer | 28 | $589 |
| Lilly USA, LLC | 33 | $547 |
| Amgen | 37 | $510 |
| Astellas Pharma US Inc | 12 | $303 |
| IBSA Pharma Inc. | 11 | $204 |
| Boehringer Ingelheim | 11 | $197 |
| Abbott | 7 | $147 |
| Johnson & Johnson | 7 | $142 |
| Biohaven Pharmaceuticals, Inc. | 8 | $139 |
| Bayer | 5 | $130 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 5 | $114 |
| Merck | 6 | $108 |
| AstraZeneca | 7 | $101 |
| Novartis | 7 | $100 |
| Aimmune Therapeutics, Inc. | 6 | $96 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $80 |
| Xeris Pharmaceuticals, Inc. | 4 | $74 |
| Sanofi-aventis U.S. LLC | 2 | $74 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $68 |
| Amarin Pharma, Inc. | 3 | $61 |
| Nestle Healthcare Nutrition Inc. | 4 | $53 |
| GRT US Holding, Inc. | 3 | $52 |
| Boston Scientific | 2 | $36 |
| Halozyme Inc | 2 | $35 |
| Sanofi Pasteur Inc. | 2 | $34 |
| Exact Sciences | 1 | $27 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $24 |
| Daiichi Sankyo Inc. | 1 | $20 |
| MVP Orthopedics Inc | 1 | $20 |
| Sumitomo Pharma America, Inc. | 1 | $20 |
| Philips North America LLC | 1 | $18 |
| Otsuka America Pharmaceutical, Inc. | 1 | $17 |
| Antares Pharma, Inc. | 1 | $16 |
| Jazz Pharmaceuticals Inc. | 1 | $13 |
How this compares
$8,693 in reported general payments places this provider in the 95th percentile of 8,062 physician assistant providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 133 | $157,136 |
| OzempicSemaglutide | 108 | $153,919 |
| JardianceEmpagliflozin | 94 | $129,217 |
| MounjaroTirzepatide | 79 | $98,699 |
| EliquisApixaban | 96 | $97,480 |
| FarxigaDapagliflozin Propanediol | 67 | $76,895 |
| OtezlaApremilast | 14 | $70,303 |
| XeljanzTofacitinib Citrate | 12 | $70,167 |
| XareltoRivaroxaban | 35 | $49,744 |
| RybelsusSemaglutide | 19 | $44,954 |
| TrulicityDulaglutide | 14 | $34,891 |
| NexlizetBempedoic Acid/Ezetimibe | 33 | $31,200 |
| Repatha SureclickEvolocumab | 24 | $30,285 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 21 | $27,920 |
| VraylarCariprazine Hcl | 16 | $27,856 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $1,447 | $198,873127 claims |
| PfizerEliquis, Xeljanz | $589 | $167,648108 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $885 | $166,819144 claims |
| Lilly USA, LLCMounjaro, Trulicity | $547 | $133,59093 claims |
| Boehringer IngelheimJardiance | $197 | $129,21794 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $101 | $104,81588 claims |
| AmgenOtezla, Prolia | $510 | $93,11627 claims |
| Johnson & JohnsonXarelto | $142 | $49,74435 claims |
| Esperion Therapeutics, Inc.Nexlizet | $692 | $31,20033 claims |
| AbbVieVraylar | $1,500 | $27,85616 claims |
| Astellas Pharma US IncMyrbetriq | $303 | $26,82026 claims |
| NovartisEntresto | $100 | $14,26215 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,062 physician assistant providers in Florida.
Other physician assistant in Port Charlotte
- Richard MarshallPort Orange$988K
- Audrey BeckerSt Augustine$689K
- Kevin WilliamsTampa$647K
- Brian BonomoLecanto$559K
- Melissa SingletonOcala$482K
- Reeli ReinuMaitland$427K
- Jeanelle KingMiami$424K
- Risha BellomoOrlando$397K
- Jason BergerClearwater$344K
- Ashley MillerGainesville$328K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.